Stage i colorectal carcinoma: VEGF immunohistochemical expression, microvessel density, and their correlation with clinical outcome

Virchows Archiv

Volumn 457, Issue 1, 2010, Pages 11-19

  Barresi, Valeria ^a,d   Di Gregorio, Carmela ^b   Regiani Bonetti, Luca ^c   Ponz De Leon, Maurizio ^c   Barresi, Gaetano ^a   Vitarelli, Enrica ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b Hospital of Carpi   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

Author keywords

CD105; Colorectal cancer; MVD; Prognosis; TNM stage; VEGF

Indexed keywords

ENDOGLIN; VASCULOTROPIN;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; SURVIVAL TIME; TUMOR LOCALIZATION; TUMOR VASCULARIZATION;

AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MICROVESSELS; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77954565320     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-010-0933-5     Document Type: Article

References (38)

1. Landis SH, Murray T, Bolden S (1999) Cancer statistics. Cancer J Clin 49:831
2. Wiggers T, Arends JW, Schutter B et al (1988) A multivariate analysis of pathologic prognostic indicators in large bowel cancer. Cancer 61:386389
3. Wu XC, Chen VW, Steele B et al (2001) Subsite-specific incidence rate and stage of disease in colorectal cancer by race, gender, and age group. Cancer 92:25472554
4. Di Gregorio C, Fante R, Roncucci L et al (1996) Clinical features, frequency and prognosis of Dukes A colorectal carcinoma: a population-based investigation. Eur J Cancer 32A:19571962
5. Di Gregorio C, Benfatti P, Losi L et al (2005) Incidence and survival of patients with DukesA (stages T1 and T2) colorectal carcinoma: a 15-year population-based study. Int J Colorectal Dis 20:147154
6. Wichmann MW, Muller C, Hornung HM (2002) The Colorectal Cancer study Group. Results of long-term follow-up after curative resection of Dukes A colorectal cancer. World J Surg 26:732736
7. Folkman J (1990) What is the evidence that tumour are angiogenesis dependent? J Natl Cancer Inst 82:46
8. Folkman J, Shing Y (1992) Angiogenesis. J Biol Chem 267:1093110934
9. Folkman J (1995) Clinical applications of angiogenesis research. N Engl J Med 333:17571763
10. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumourigenesis. Cell 86:353364
11. Ferrara N, Davis-Smith T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18:425
12. Fan F, Wey JS, McCarty MF et al (2005) Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 24:26472653
13. Cheifetz S, Bellon T, Cales C et al (1992) Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 267:1902719030
14. Burrows FJ, Derbyshire EJ, Tazzari PL et al (1995) Up-regulation of endoglin on vascular endothelial cells in human solid tumours: implications for diagnosis and therapy. Clin Cancer Res 1:16231634
15. Miller DW, Graulich W, Karges B (1999) Elevated expression of endoglin, a component of the TGF-β receptor complex, correlates with proliferation of tumour endothelial cells. Int J Cancer 81:568572
16. Minhajat R, Mori D, Yamasaki F (2006) Endoglin (CD105) expression in angiogenesis of colon cancer: analysis using tissue microarrays and comparison with other endothelial markers. Virchows Arch 448:127134
17. Saad RS, Liu YL, Nathan G et al (2004) Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol 17:197203
18. Sobin LH, Wittekind C (eds) (2002) TNM classification of malignant tumors. International Union Against Cancer (UICC), 6th edn. Wiley-Liss, New York
19. Ponz de Leon M, Sassatelli R, Sacchetti C (1989) Familial aggregation of tumors in the three-year experience of a populationbased colorectal cancer registry. Cancer Res 49:43444348
20. Ponz de Leon M, Benatti P, Percesepe A (1999) Epidemiology of cancer of the large bowelthe 12-year experience of a specialized registry in northern Italy. Ital J Gastroenterol Hepatol 31:1018
21. Barresi V, Vitarelli E, Cerasoli S (2009) Semaphorin3A immunohistochemical expression in human meningiomas: correlation with the microvessel density. Virchows Arch 454:563571
22. Barresi V, Tuccari G (2010) Increased ratio of vascular endothelial growth factor to semaphorin3A is a negative prognostic factor in human meningiomas. Neuropathology. doi:10.1111/j.1440- 1789.2010.01105.x
23. Barresi V, Cerasoli S, Vitarelli E et al (2007) Density of microvessel positive for CD105 (endoglin) is related to prognosis in meningiomas. Acta Neuropathol 114:147156
24. Barresi V, Cerasoli S, Tuccari G (2008) Correlative evidence that tumour cell-derived caveolin-1 mediates angiogenesis in meningiomas. Neuropathology 28:472478
25. Torsney E, Charlton R, Parums D et al (2002) Inducible expression of human endoglin during inflammation and wound healing in vivo. Inflamm Res 51:464470
26. Fonsatti E, Del Vecchio L, Altomonte M (2001) Endoglin: an accessory component of the TGF-β-binding receptor complex with diagnostic, prognostic, and bio-immunotherapeutic potential in human malignancies. J Cell Physiol 188:17
27. Takahashi Y, Kitadai Y, Bucana CD et al (1995) Expression of vascular endothelial growth factor and its receptors, KDR, correlates with vascularity, metastasis and proliferation of human colon cancer. Cancer Res 55:39643968
28. Takahashi N, Haba A, Matsuno F et al (2001) Antiangiogenic therapy of established tumours in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res 61:78467854
29. Kang SM, Maeda K, Onoda N (1997) Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumour vascularity and liver metastasis. Int J Cancer 74:502507
30. Dassoulas K, Gazouli M, Theodoropoulos G (2010) Vascular endothelial growth factor and endoglin expression in colorectal cancer. J Cancer Res Clin Oncol 136:703708
31. Ishigami SI, Arii S, Furutani M et al (1998) Predictive value of vascular endothelial growth factor (VEGF) for metastasis and prognosis of human colorectal cancer. Br J Cancer 78:13791384
32. Weidner N, Semple JP, Welch WR (1991) Tumour angiogenesis and metastasiscorrelation in invasive breast carcinoma. N Engl J Med 324:18
33. Shih T, Lindley C (2006) Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28:17791802
34. Bose D, Meric-Bernstam F, Hofstetter W et al (2010) Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol 11:373 382
35. WangY FD, Vanderlaan M et al (2004) Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7:335345
36. Jain RK (2003) Molecular regulation of vessel maturation. Nat Med 9:685693
37. Gerber HP, Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65:671680
38. Uneda S, Toi H, Tsujie T et al (2009) Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumours by targeting tumour vasculature. Int J Cancer 125:1446 1453